NCT07024615View on ClinicalTrials.gov

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

ASP2138

Subcutaneously

DRUG

Oxaliplatin

Injection

DRUG

Leucovorin

Injection

DRUG

5-FU

Injection

DRUG

Irinotecan

Injection

DRUG

Gemcitabine

Intravenously

DRUG

Nab-paclitaxel

Intravenously

DRUG

Capecitabine

Oral

Trial Locations (2)

27710

RECRUITING

Duke University Medical Center - Duke Cancer Center, Durham

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT07024615 - A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | Biotech Hunter | Biotech Hunter